Literature DB >> 24599135

Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.

C Faveeuw1, F Trottein.   

Abstract

α-Galactosylceramide (α-GalCer) represents a new class of immune stimulators and vaccine adjuvants that activate type I natural killer T (NKT) cells to swiftly release cytokines and to exert helper functions for acquired immune responses. This unique property prompted clinicians to exploit the antitumor potential of NKT cells. Here, we review the effects of α-GalCer in (pre)clinics and discuss current and future strategies that aim to optimize NKT cell-mediated antitumor therapy, with a particular focus on cell-based and nanovector vaccines. ©2014 AACR.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24599135     DOI： 10.1158/0008-5472.CAN-13-3504

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  13 in total

1.  α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Authors:  Vanessa Sainz; Liane I F Moura; Carina Peres; Ana I Matos; Ana S Viana; Angela M Wagner; Julia E Vela Ramirez; Teresa S Barata; Manuela Gaspar; Steve Brocchini; Mire Zloh; Nicholas A Peppas; Ronit Satchi-Fainaro; Helena F Florindo
Journal:  Acta Biomater       Date:  2018-06-22       Impact factor: 8.947

Review 2.  Development of individualized anti-metastasis strategies by engineering nanomedicines.

Authors:  Qianjun He; Shengrong Guo; Zhiyong Qian; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2015-06-09       Impact factor: 54.564

Review 3.  Glycolipid activators of invariant NKT cells as vaccine adjuvants.

Authors:  Shalu Sharma Kharkwal; Pooja Arora; Steven A Porcelli
Journal:  Immunogenetics       Date:  2016-07-05       Impact factor: 2.846

Review 4.  NKT cell networks in the regulation of tumor immunity.

Authors:  Faith C Robertson; Jay A Berzofsky; Masaki Terabe
Journal:  Front Immunol       Date:  2014-10-28       Impact factor: 7.561

Review 5.  Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Authors:  Mérédis Favreau; Karin Vanderkerken; Dirk Elewaut; Koen Venken; Eline Menu
Journal:  Oncotarget       Date:  2016-04-26

6.  Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.

Authors:  Adeline Barthelemy; Stoyan Ivanov; Maya Hassane; Josette Fontaine; Béatrice Heurtault; Benoit Frisch; Christelle Faveeuw; Christophe Paget; François Trottein
Journal:  MBio       Date:  2016-11-01       Impact factor: 7.867

Review 7.  Natural Killer T Cells in Cancer Immunotherapy.

Authors:  Shiny Nair; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2017-09-22       Impact factor: 7.561

Review 8.  The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation.

Authors:  Catherine Gottschalk; Elisabeth Mettke; Christian Kurts
Journal:  Front Immunol       Date:  2015-07-28       Impact factor: 7.561

9.  Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo.

Authors:  Zhengyu Jiang; Hongxia Zhang; Ye Wang; Bin Yu; Chen Wang; Changcheng Liu; Juan Lu; Fei Chen; Minjun Wang; Xinlu Yu; Jiahao Lin; Xinghua Pan; Pin Wang; Haiying Zhu
Journal:  Oncotarget       Date:  2016-02-23

10.  A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model.

Authors:  Xiangshu Wen; Seil Kim; Ran Xiong; Michelle Li; Agnieszka Lawrenczyk; Xue Huang; Si-Yi Chen; Ping Rao; Gurdyal S Besra; Paolo Dellabona; Giulia Casorati; Steven A Porcelli; Omid Akbari; Mark A Exley; Weiming Yuan
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.